medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2016, Number 4

<< Back Next >>

Rev Esp Med Quir 2016; 21 (4)

Frequency of abnormal calcium-phosphorus product in pre-dialysis patients

López-Mendoza M, RoblesÁlvarez JG, Rosas-Barrientos JV

Language: Spanish
References: 43
Page: 127-135
PDF size: 157.34 Kb.


ABSTRACT

Introduction: Chronic kidney disease is a problem of international public health that affects 5-10% of the world population. Bone mineral disease is common in patients with CKD and has been implicated as a risk factor for mortality. It is manifested by alterations of calcium phosphorus product.
Objetive: To report the frequency of disorders of the calcium phosphorus product in patients before dialysis in the Hospital Regional 1° de Octubre.
Methods: Cross-sectional study where the research unit were clinical records of patients over 18 years seen in Nephrology department, with stage KDOQI 3-4, biochemical measurements and records of patients with CKD are excluded with substituted renal function, autoimmune diseases, oncological comorbidities, bone disease other than chronic kidney disease, or chronic steroid treatment causes. Sociodemographic, clinical, used for control of mineral bone disease and biochemical drugs were included, GFR was calculated. Statistical analysis included frequency measurements, central tendency, dispersion, normality tests and chi-square inference, Mann-Whitney U, both the alpha was 0.05.
Results: The mean age was 64.2 ± 14 years, 47 men (49%), 45 women (51%), the most common cause of CKD was hypertension 18 (19.6%). In 12 (13%) cases calcium-phosphorus product was ≥ 55 (13%).
Conclusion: ≥ 55 calcium-phosphorus product was found in cases with longer CKD and GFR decreased.


REFERENCES

  1. National Kidney Foundation K/DOQI Clinical Practice for Chronic Kidney Disease: Evaluation, Classification and Stratifacation Am J Kidney Dis. 2002;39Suppl1:S1-S266.

  2. Wild C. Diabetic nephropathy-who cares? EDTNA/ERCA J. 2004;30:163-5.

  3. Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives –a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247-59.

  4. Coresh J, Selvin E, Stevens L. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038–47.

  5. United States Renal Data System. Patient mortality and survival in ESRD. Am J Kidney Dis. 1999;34:74-86.

  6. Fundación Mexicana del Riñón AC. [homepage en internet] México: Disponible en www.fundenrenal.org.mx.

  7. Amato D, Álvarez-Aguilar C, Castañeda-Limones R. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int. 2005;68:S11-7.

  8. Méndez A, Méndez J, Tapia T, Muñoz A, Aguilar L. Epidemiología de la insuficiencia renal crónica en México. Diálisis y transplante. 2010;31:7-11.

  9. Cueto A, Cortés L, Martínez H. Detection of early nephopathy in Mexican type 2 Diabetes mellitus patients. Kidney Int. 2005:68Suppl97:S40-5.

  10. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney International. 1999;56:S14-9.

  11. Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone. 2009;44:666 –70.

  12. Bilezikian J, Marcus R. The parathyroids: basic and clinical concepts. En: Bilezikian JP, editores. San Diego: Academic Press; 2001. p. 167-82.13.

  13. Treviño A. Insuficiencia renal crónica: enfermedad emergente, catastrófica y por ello prioritaria. Cir Ciruj. 2004;72:3-4.

  14. Owda A. Elhwairis H. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25:595-602.

  15. Kovesdy CP, Kalantar-Zadeh K. Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 2008;40:427– 40.

  16. Saliba W, El Haddad B. Secondary Hyperparathyroidism: Pathophysiology and Treatment. JABFM. 2009;22:574-80.

  17. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis. 1997;30:606-20.

  18. Levin A, Backris GL, Molitch M. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kideny Int. 2007;71:31-8.

  19. Martínez I, Saracho R, Montenegro J. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496-502.

  20. Sharon M, Moe M, Stuart M. Chronic Kidney Disease – Mineral Bone Disorder. En: Taal M, Chertow G, Marsden P, editores. Brenner & Rector´s The Kidney. Philadelphia: Elservier; 2012. p. 2021-58.

  21. Pisoni R, Satayathum S. Predictos of hyperphosphatemia and its association with cardiovascular deaths and hospitalization in chronic hemodialysis patients: International results from the DOPPS. Neprhol Dial Transplant. 2003;18Suppl4:678. 22.

  22. Hruska K, Teitelbaum S. Renal osteodistrophy. N Engl J Med. 1995;333:166-74.

  23. Walters B, Danese M. Patient prevalence within proposed NFK-KDOQI guidelines for bone metabolism and disease. J Am Soc Nephrol. 2003;14:473A-4A.

  24. Torregrosa J, Andia J. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con Enfermedad Renal Crónica. Nefrología. 2008;28Suppl1:1-22.

  25. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). Kidney International. 2003;76:113.

  26. Felsenfeld AJ. Considerations for the treatment of secondary hyperparathyroidism in renal failure. J Am Soc Nephorl. 1997;8:993-1004.

  27. Friedman E. Consequences an management of hyperphosphatemia in patients with renal insufficiency. Kidney International. 2005;67:S1-7.

  28. Cunningham J. Achieving Therapeutic targets in the treatment of secondary hyperpharathyroidism. Nephrol Dial Transplant. 2004;19:V9-14.

  29. Sprague S, Lerma E. Suppression of parathyroid hormone secretion in hemodialysis patients: comparision of paracalcitol with calcitriol. Am J Kidney Dis. 2001:38Suppl5:S51-6.

  30. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96.

  31. Delmez J,Block G,Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer A. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91.

  32. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009;4:178-85.

  33. Frazao J, Chesney R. Intermittent oral 1 alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in hemodialysis patients. 1 alphaD2 study group. Nephrol Dial. Transplant. 1998;13Suppl3:68-72.

  34. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446–56.

  35. Goodman W, Turner S. Future role of calcimimetics in end stage renal disease. Adv Renal Replace Ther. 2002;9:200-8.

  36. Block G, Zeig S. Combined Therapy with cinaclacet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008;23:2311-8.

  37. Moe S, Chertow G, Coburn J, Quarles L, Goodman W, Block G. Achieving NKFK/ DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 2005;67:760-71.

  38. Kostakis A, Vaiopoulos G, Kostantopoulos K, Zavos G, Bocos I, Sgouromalis S. Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure. Int Surg 1997;82:85-6.

  39. Ureña P, Jacobson S. Cinacalcet and achievement of the NFK/K-DOQI recommended target values for bone and mineral metabolism in real world clinical practice- ECHO observational study. Neprol Dial Transplant. 2009;24:2852-9.

  40. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42:S1-170.

  41. Kestenbaum B, Sampson JN, Rudser KD. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.

  42. Menon V, Greene T, Pereira AA. Relationship of phosphorus and calciumphosphorus product with mortality in CKD. Am J Kidney Dis. 2005;46:455-463.

  43. Voormolen N, Noordzij M, Grootendorst DC. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007;22:2909-2916.




2020     |     www.medigraphic.com